The effect of oestradiol implants on regional and total bone mass: a three‐year longitudinal study

Ryde, S. J. S.; Bowen-Simpkins, K.; Bowen-Simpkins, P; Evans, W. D.; Morgan, W. D.; Compston, JE

doi:10.1111/j.1365-2265.1994.tb02440.x

Cited by 19 publications

(13 citation statements)

References 40 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In postmenopausal women a decrease in femoral neck BMD by one standard deviation from the age-adjusted mean increases the risk of hip fracture by a factor of 2.6 170]. Postmenopausal oestrogen therapy prevents bone loss [71][72][73] and reduces the incidence of bone fracture |74|. Oral oestrogen 17 11. transdermal oestrogen 1721 and oestro gen implants |73| are all ellective in preserving bone mass in postmenopausal women.…”

Section: Sex Steroidsmentioning

confidence: 99%

Role of Growth Hormone and Sex Steroids in Achieving and Maintaining Normal Bone Mass

Holmes

Shalet

1996

Horm Res

View full text Add to dashboard Cite

It is now established that adults with growth hormone (GH) deficiency, of childhood or adult onset, have reduced bone mass. GH deficiency is believed to interfere with acquisition of bone mass, although an alternative mechanism is required to explain the reduction in bone mass present in adults who acquire GH deficiency after peak bone mass has been achieved. GH replacement increases bone turnover and may increase bone mass in the longer term, although short-term studies show a decrease in bone mass which can be explained by an increase in bone resorption before new bone formation occurs. Abnormalities of GH secretion have also been implicated in the development of osteoporosis, but the effect of GH treatment on bone mass in such patients is disappointing. Sex steroids have an important role to play in the acquisition of bone mass, and reduced sex steroid levels during adolescence have a deleterious effect on bone mass. The importance of sex steroids in the maintenance of bone mass is illustrated by the development of osteopenia in men and women with hypogonadism, and by the preservation of bone mass by restoration of normal endogenous sex steroid levels, or by treatment with exogenous sex steroid. Sex steroids also influence circulating levels of GH and insulin-like growth factor-1, and the interaction between these hormones is likely to be important in the acquisition and maintenance of normal bone mass.

show abstract

Section: Sex Steroidsmentioning

confidence: 99%

Role of Growth Hormone and Sex Steroids in Achieving and Maintaining Normal Bone Mass

Holmes

Shalet

1996

Horm Res

View full text Add to dashboard Cite

show abstract

“…Replacement of oestrogen, and more specifically oestradiol, which is the major oestrogen in premenopausal women, can prevent the symptoms of menopause [5] and is thought to have a beneficial effect on the incidence of osteoporosis [6][7][8] and cardiovascular disease in postmenopausal women.…”

Section: Discussionmentioning

confidence: 99%

“…Blood samples were taken prior to patch application, then 1, 2, 3, 4,6,8,10,12,16,20,24,36,48,72,96,120,144,168,180,192 and 216 h after application. The primary pharmacokinetic parameters C max (mean peak plasma concentration) and AUC 0-168 (area under the plasma concentration curve from the time of application to the time of removal) were calculated with and without correction for baseline.…”

Section: Methodsmentioning

confidence: 99%

“…Hormone-replacement therapy (HRT) reverses the symptoms of menopause by replenishing oestradiol to premenopausal levels. Moreover, there is epidemiological evidence to suggest that HRT reduces climacteric symptoms [5], the development of osteoporosis [6][7][8], and the risk of cardiovascular disease [9][10][11][12] in postmenopausal women.…”

Section: Introductionmentioning

confidence: 99%

“…Gynecol Obstet Invest 1999;48: [1][2][3][4][5][6] Geyer/Gerrits/Renoux/Uhl ty. A total of 280 adverse events were reported during the 13-week study following the administration of the four different doses of Fem7.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Pharmacokinetics of Fem7<sup>®</sup>, a Once-Weekly, Transdermal Oestrogen Replacement System in Healthy, Postmenopausal Women

Geyer

Gerrits²,

Renoux³

et al. 1999

Gynecol Obstet Invest

View full text Add to dashboard Cite

This open-label, randomized study in 36 healthy postmenopausal women, investigated the pharmacokinetics of Fem7^® (an oestradiol matrix-type patch), at doses of 25, 50, 75 and 100 μg/24 h, applied once weekly. Maximum plasma concentrations of oestradiol and oestrone were observed 14–20 h after patch application, remaining within the therapeutic range until removal, and returning to baseline within 12 h thereafter. Plasma oestradiol concentrations increased in a dose-dependent manner for all four doses, and plasma oestrone increased for the three highest doses. Fem7 treatment was well tolerated at all four doses and no severe adverse reactions were reported. Fem7 is a convenient and well-tolerated form of hormone-replacement therapy that delivers oestradiol in a consistent and predictable manner.

show abstract

Atlas of Osteoporosis

Orwoll¹

2003

View full text Add to dashboard Cite

The effect of oestradiol implants on regional and total bone mass: a three‐year longitudinal study

Cited by 19 publications

References 40 publications

Role of Growth Hormone and Sex Steroids in Achieving and Maintaining Normal Bone Mass

Role of Growth Hormone and Sex Steroids in Achieving and Maintaining Normal Bone Mass

Pharmacokinetics of Fem7<sup>®</sup>, a Once-Weekly, Transdermal Oestrogen Replacement System in Healthy, Postmenopausal Women

Atlas of Osteoporosis

Contact Info

Product

Resources

About